Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Anti-Fibrotic Agent PLN-74809

Trial Profile

A Phase 1, First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Anti-Fibrotic Agent PLN-74809

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs PLN-74809 (Primary)
  • Indications Idiopathic pulmonary fibrosis; Primary sclerosing cholangitis
  • Focus Adverse reactions; First in man
  • Sponsors Pliant Therapeutics
  • Most Recent Events

    • 03 Jan 2019 According to a Pliant Therapeutics media release, the first investigational new drug application for PLN-74809 was submitted based on positive preclinical studies.
    • 03 Jan 2019 According to a Pliant Therapeutics media release, the first cohort of subjects in this trial has been dosed.
    • 03 Jan 2019 Status changed from planning to recruiting, according to a Pliant Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top